ApheaBio和拜耳将共同开发生物杀虫剂。
ApheaBio宣布与拜耳公司建立研究合作伙伴关系，旨在加速开发针对刺吸式害虫的生物杀虫剂。该协议针对的是具有重大经济影响的农业害虫。此次合作旨在拓展农户可用的作物保护工具。
【中国创制】两款新农化分子获ISO通用名正式批准，分属江苏农研所、辽宁先达
世界农化网中文网报道：日前，ISO正式批准了2种创制农药活性成分的通用名，包括江苏省农药研究所股份有限公司的杀菌剂amfenamacril和辽宁先达化工有限公司的除草剂triflupyroxazin。
FAO Urges Open Trade On All Agricultural Inputs And Efficient Fertilizer Use Amid Global Food Production Risks
June 2026, Rome: The Director-General of the Food and Agriculture Organization (FAO), QU Dongyu, today opened the 1…
高含量农药产品登记被拒！印尼农业部2019年未成文草案隐性落地
世界农化网中文网报道：2026年近期的登记实操中，天昱小伙伴儿发现印尼农业部以含量超出允许登记的上限为理由，拒绝了部分的登记申请。
印度农化监管动态：苯啶菌酮、氟苯虫酰胺等多款关键分子获登；生产设施强制地理标记
世界农化网中文网报道：2026年4月，印度中央杀虫剂理事会及登记委员会（CIB&RC）第471次登记委员会（RC）会议召开，批准了包括杀菌剂、杀虫剂、除草剂及种子处理剂在内的多款产品登记申请。同时，RC明确了生产设施地理标记（Geo-Tagging）的强制要求，以提升监管透明度。
欧盟委员会通过植保产品标签新规，数字标签强制化与风险导向重构
世界农化网中文网报道：欧盟委员会于2026年5月26日正式通过《法规 (EU) 2026/1123》，对植物保护产品标签制度实施全面改革。该法规将取代现行《法规 (EU) No 547/2011》，自公布之日起第20天生效，并自2028年1月1日起适用。其中，数字标签等部分条款将分阶段推进，至2030年1月1日完成全面落地。
Future Food Quick Bites: Slutty Vegan, Protein Bars & Plant-Based Subway
Pinky Cole‘s plant-based fast-food chain, Slutty Vegan, has signed franchise deals to open new locations in Washington, DC and Atlanta, and announced plans to relocate its Baltimore restaurant to a new site at the campus of Johns Hopkins Hospital in 2027.
Oatly Executives Said to Be Weighing Buyout of Greater China Business
Executives overseeing Oatly Group AB’s Greater China operations are reportedly considering a management buyout of the business, according to Bloomberg, which cited people familiar with the matter. The potential buyers are working toward a deal that could close before the end of 2026, though discussions remain ongoing and no agreement is guaranteed.
Spanish Plant-Based Association Partners With Alimentaria FoodTech Ahead of October Event
Spain’s plant-based food and beverage trade body has formalised a partnership with Alimentaria FoodTech ahead of the Barcelona food technology fair scheduled for October.
Beyond amyloid and dopamine: emerging technologies reshaping neurology
For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development centered on dopamine signaling. Rare disease programs often focused on replacing a missing protein or gene.